Regeneron Pharmaceuticals (NASDAQ:REGN) Issues Earnings Results

Regeneron Pharmaceuticals (NASDAQ:REGN) released its earnings results on Friday. The biopharmaceutical company reported $20.07 EPS for the quarter, topping analysts’ consensus estimates of $16.51 by $3.56, FiscalAI reports. Regeneron Pharmaceuticals had a return on equity of 13.47% and a net margin of 27.86%. The firm had revenue of $5.12 billion for the quarter, compared to analysts’ expectations of $4.58 billion. During the same period in the prior year, the firm posted $11.83 earnings per share. The company’s quarterly revenue was up 36.3% on a year-over-year basis.

Here are the key takeaways from Regeneron Pharmaceuticals’ conference call:

• Regeneron reported a strong third quarter, with total revenue up 36% to $5.1 billion and non-GAAP EPS up 70% to $20.07. Dupixent, EYLEA HD, and LIBTAYO each reached record quarterly sales.
• Dupixent sales grew 35% globally at constant currency to $6.5 billion, while U.S. EYLEA HD sales rose 62% to approximately $700 million and LIBTAYO sales increased 51% globally. Management expects continued EYLEA HD momentum and anticipates a potential prefilled-syringe approval before year-end.
• The pipeline produced encouraging data across several potential growth drivers, including approximately 70% liver-fat reduction for the genetically validated CIDEB siRNA, roughly 70% response rates for ubamatamab in low-grade serous ovarian cancer, and planned pivotal development for POTS and multiple myeloma programs.
• Regeneron expanded its Sanofi alliance to develop four next-generation, longer-acting type 2 inflammation antibodies, with Regeneron recording a $1 billion upfront payment in the fourth quarter and sharing future development costs and global profits equally.
• EYLEA’s U.S. sales fell 41% year over year to $400 million, with further low- to mid-teens sequential demand declines expected in the fourth quarter as aflibercept biosimilar competition increases. Regeneron also expects 2027 R&D expense to rise by a mid-teens percentage as it advances more than 15 Phase III trials.

Regeneron Pharmaceuticals Price Performance

Shares of REGN stock opened at $927.89 on Friday. Regeneron Pharmaceuticals has a twelve month low of $591.52 and a twelve month high of $935.35. The company has a quick ratio of 2.78, a current ratio of 3.34 and a debt-to-equity ratio of 0.06. The business has a fifty day simple moving average of $793.30 and a 200 day simple moving average of $738.05. The company has a market cap of $95.54 billion, a P/E ratio of 20.49, a P/E/G ratio of 1.57 and a beta of 0.16.

Insider Activity at Regeneron Pharmaceuticals

In related news, EVP Marion Mccourt sold 1,215 shares of Regeneron Pharmaceuticals stock in a transaction dated Wednesday, September 2nd. The stock was sold at an average price of $850.00, for a total value of $1,032,750.00. Following the completion of the sale, the executive vice president directly owned 13,134 shares in the company, valued at approximately $11,163,900. This trade represents a 8.47% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Andrew Murphy sold 4,147 shares of the company’s stock in a transaction dated Wednesday, October 14th. The shares were sold at an average price of $772.70, for a total transaction of $3,204,386.90. Following the transaction, the insider owned 47,833 shares in the company, valued at approximately $36,960,559.10. This trade represents a 7.98% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 8,093 shares of company stock valued at $6,506,845 over the last quarter. Company insiders own 6.97% of the company’s stock.

Analysts Set New Price Targets

REGN has been the subject of a number of research reports. The Goldman Sachs Group upped their target price on shares of Regeneron Pharmaceuticals from $965.00 to $972.00 and gave the company a “buy” rating in a report on Friday, July 31st. Leerink Partners lifted their price target on Regeneron Pharmaceuticals from $641.00 to $824.00 and gave the stock a “market perform” rating in a report on Monday, August 17th. Raymond James Financial boosted their price target on shares of Regeneron Pharmaceuticals from $902.00 to $911.00 and gave the stock an “outperform” rating in a report on Friday, July 31st. Weiss Ratings reaffirmed a “hold (c)” rating on shares of Regeneron Pharmaceuticals in a research note on Monday, September 21st. Finally, Cantor Fitzgerald upped their target price on shares of Regeneron Pharmaceuticals from $750.00 to $795.00 and gave the stock an “overweight” rating in a research note on Friday, July 31st. One equities research analyst has rated the stock with a Strong Buy rating, twenty-two have assigned a Buy rating and eight have assigned a Hold rating to the company’s stock. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average target price of $850.83.

Key Regeneron Pharmaceuticals News

Here are the key news stories impacting Regeneron Pharmaceuticals this week:

• Positive Sentiment: Q3 earnings and revenue beat expectations: Regeneron reported $5.12 billion in revenue, up 36.3% year over year and well above the approximately $4.56 billion analyst consensus. Non-GAAP EPS was $20.07, compared with estimates near $16.42 and $11.83 a year earlier. REGN Q3 Earnings Beat on Dupixent Profits & Eylea HD Growth, Stock Up
• Positive Sentiment: Strong commercial performance: Sanofi-partnered Dupixent generated robust demand, while U.S. Eylea HD sales increased 62% to $699 million and global Libtayo sales rose 51% to $550 million. The results suggest Regeneron’s product portfolio is offsetting competitive and pricing pressures in older treatments. Regeneron Reports Third Quarter 2026 Financial and Operating Results
• Positive Sentiment: Pipeline and strategic momentum: Regeneron highlighted progress toward upcoming FDA catalysts, expanded its Sanofi collaboration with next-generation long-acting immunology antibodies and received a $1 billion upfront payment to be recognized as collaboration revenue. A new Phase 2 cemiplimab combination study also expands its skin-cancer pipeline. Regeneron Expands Skin Cancer Pipeline With New Cemiplimab Combo Trial
• Neutral Sentiment: Management characterized 2026 as potentially one of Regeneron’s strongest years, and analysts have raised some expectations following the earnings beat. Investors will now focus on whether Dupixent growth and new launches can remain durable.
• Negative Sentiment: Eylea 2 mg remains exposed to biosimilar competition, while at least one analyst recently lowered Regeneron’s price target from $900 to $850. After the sharp upward move, valuation and the need for continued execution could create near-term volatility. Evercore ISI Adjusts Price Target on Regeneron Pharmaceuticals

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc is a biotechnology company that discovers, develops and commercializes medicines for serious medical conditions. The company uses genetic and antibody-based research technologies to develop treatments in areas including eye diseases, allergic and inflammatory conditions, cancer, cardiovascular disease, infectious diseases and rare disorders.

Its marketed products include Eylea and Eylea HD for retinal diseases, Dupixent for several inflammatory and allergic conditions, Libtayo for certain cancers, Praluent for cardiovascular disease, Kevzara for rheumatoid arthritis, and other medicines such as Inmazeb, Evkeeza, Veopoz and Arcalyst.